title: Defining a future role for radiogenic therapy.
abstract: The goal of cancer therapy is to eliminate the cancer and/or to arrest further growth while decreasing normal tissue toxicity, i.e. to increase the therapeutic ratio. This review focuses on a group of therapeutics that are either (1) directly stimulated by radiation to produce either directly or indirectly cytotoxic agents (i.e. genes under the control of a radiation inducible promoter that produce a cytotoxic protein or an enzyme that converts a prodrug to an active form, respectively); (2) auger-electron emitting radiolabelled oligonucleotides, antibodies, nucleotide analogues, or other small molecules that are internalized; (3) radiation inducible genes that produce a ligand or transporter (or the like) which then can be targeted by cytotoxic agents (e.g. radiolabelled substance). We have termed this group of therapeutics radiogenic therapy.
authors.affiliation: Department of Radiology, Medical College of Georgia, Augusta 30912, USA. JM_Kaminski@FCCC.edu
authors.forename: J M
authors.initials: JM
authors.lastname: Kaminski
authors.forename: R J
authors.initials: RJ
authors.lastname: Kaminski
authors.forename: A P
authors.initials: AP
authors.lastname: Dicker
authors.forename: J L
authors.initials: JL
authors.lastname: Urbain
mesh_terms: D003131:Combined Modality Therapy / Q000639:trends; D015316:Genetic Therapy / Q000639:trends*; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D018787:Radiation Oncology / Q000639:trends; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D011878:Radiotherapy / Q000639:trends*
chemical_list: D019275:Radiopharmaceuticals